Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.

Arakawa-Todo M, Yoshizawa T, Zennami K, Nishikawa G, Kato Y, Kobayashi I, Kajikawa K, Yamada Y, Matsuura K, Tsukiyama I, Saito H, Hasegawa T, Nakamura K, Sumitomo M.

Anticancer Res. 2013 Nov;33(11):5043-50.

PMID:
24222148
2.

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ.

J Natl Cancer Inst. 2011 May 4;103(9):763-73. doi: 10.1093/jnci/djr128. Epub 2011 Apr 28.

3.
4.

Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.

Yildiz I, Sen F, Basaran M, Ekenel M, Agaoglu F, Darendeliler E, Tunc HM, Ozcan F, Bavbek S.

Jpn J Clin Oncol. 2011 Dec;41(12):1380-7. doi: 10.1093/jjco/hyr151. Epub 2011 Oct 19.

PMID:
22013228
5.

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.

Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, Na S, Kim CS, Hong JH, Hong B, Song C, Ahn H.

Jpn J Clin Oncol. 2010 Oct;40(10):980-5. doi: 10.1093/jjco/hyq073. Epub 2010 May 10.

PMID:
20457723
6.
7.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.

Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E.

J Urol. 2014 Mar;191(3):611-8. doi: 10.1016/j.juro.2013.08.090. Epub 2013 Sep 7.

8.

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.

Cancer. 2012 Mar 1;118(5):1252-9. doi: 10.1002/cncr.26440. Epub 2011 Sep 6.

9.

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.

J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3.

PMID:
19652072
10.

Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.

Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K, Tanabe K.

Jpn J Clin Oncol. 2014 Mar;44(3):270-7. doi: 10.1093/jjco/hyt232. Epub 2014 Jan 27.

PMID:
24474815
11.

Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.

Sternberg CN, CalabrĂ² F, Bracarda S, Cartenì G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C.

Oncology. 2015;88(5):273-80. doi: 10.1159/000369256. Epub 2015 Jan 15.

PMID:
25592399
12.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.

Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee.

Eur J Cancer. 2014 Mar;50(4):746-52. doi: 10.1016/j.ejca.2013.11.029. Epub 2013 Dec 11.

PMID:
24332573
13.
14.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS.

Cancer Med. 2014 Dec;3(6):1517-26. doi: 10.1002/cam4.302. Epub 2014 Jul 18.

15.

Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.

Park S, Lee J, Park SH, Park JO, Kang WK, Park YS, Cho JH, Lim HY.

Chemotherapy. 2010;56(6):485-91. doi: 10.1159/000321033. Epub 2010 Nov 24.

PMID:
21099221
16.

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.

Miyake H, Kusuda Y, Harada K, Sakai I, Fujisawa M.

Int J Clin Oncol. 2013 Feb;18(1):81-6. doi: 10.1007/s10147-011-0347-7. Epub 2011 Nov 18.

PMID:
22095244
17.

Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.

Zhang CJ, Zhao PJ, Li XS, Zhao J, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, He ZS, Jin J, Zhou LQ.

Chin Med J (Engl). 2013;126(15):2826-9.

PMID:
23924450
18.

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.

Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.

BMC Cancer. 2011 Mar 24;11:105. doi: 10.1186/1471-2407-11-105.

19.
20.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S.

BJU Int. 2011 Oct;108(8):1279-83. doi: 10.1111/j.1464-410X.2010.09990.x. Epub 2011 Jan 18.

Supplemental Content

Support Center